The use of pigs for human transplants stems from a historical partnership between the Mayo Clinic and Hormel Foods to breed smaller 'minipigs' for lab research. This agricultural project, combined with pigs' anatomical similarities and lower disease-transmission risk compared to primates, established them as the primary source for replacement organs.

A convergence of DNA sequencing, CRISPR, and AI allows scientists to move beyond just understanding biology to actively intervening. Medicine is now programming cellular behavior by rewriting DNA, representing a "step function" leap in what's achievable for treating disease at its root cause.

Unlike direct-to-patient cell therapies, xenotransplantation's process of creating a pig serves as a biological filter. If gene edits have significant off-target effects, a healthy animal cannot be produced. This 'viable animal' checkpoint validates the genetic engineering before clinical use.

Instead of using CRISPR for gene editing (cut and replace), Seek Labs harnesses its natural function. Their platform programs CRISPR to find and 'chop up' viral DNA and RNA, directly lowering the viral load and allowing the host's immune system to take over.

A major unknown was the surgical procedure itself. After four cases, surgeons report that transplanting a pig kidney is remarkably similar to a human-to-human allogeneic transplant. This de-risks the surgical component significantly, with patients often leaving the ICU in one night.

CRISPR's origins lie in basic microbiology. Scientists studying unusual repeating DNA sequences in bacteria discovered they were part of an adaptive immune system. Bacteria use CRISPR to recognize and cut the DNA of invading viruses (bacteriophage), a mechanism that was then repurposed for gene editing.

Delivering the CRISPR-Cas9 complex into delicate primary human T-cells was a major hurdle. The solution was electroporation, an old technique that uses an electrical current to create temporary pores in the cell membrane, allowing the CRISPR machinery to enter. This non-obvious method unlocked T-cell engineering.

Advanced gene-editing techniques like CRISPR have a key advantage over traditional GMOs in winning consumer trust. Instead of adding genes from foreign organisms—the source of the "Frankenfood" stigma—CRISPR allows scientists to simply delete or switch off a single, existing gene. This distinction may allow producers to bypass negative consumer perceptions.

Patrick Collison believes we can finally cure complex diseases because biology now has a complete 'Turing loop': advanced sequencing to 'read' biological data, neural networks to 'think' about it, and CRISPR to 'write' changes by perturbing cells. This combination provides the necessary toolset for breakthroughs.